CD274 and neoplasm: Pembrolizumab monotherapy has become a standard first-line treatment for advanced NSCLC in patients with a PD-L1 tumor proportion score (TPS) of at least 50%, based on the results of the KEYNOTE-024 phase III trial (Reck et al. 2016).